Skip to content

Oxytocin and Social Behavior Over the Lifespan

Oxytocin and Social Behavior Over the Lifespan: Interventional Study

Status
Completed
Phases
Early Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00914953
Enrollment
41
Registered
2009-06-05
Start date
2010-02-28
Completion date
2011-12-31
Last updated
2012-03-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Social Activity

Keywords

social isolation, cooperative behavior, depression, loneliness, happiness, empathy

Brief summary

This study will investigate if intranasal oxytocin (a hormone naturally produced in the body) promotes motivation for, and engagement in, social activities in older adults.

Detailed description

Using a double-blind and placebo controlled design, this study seeks to determine if a short course of exogenous oxytocin (OT) will induce changes in social activities in residentially housed older adults (OAs) during a 10-day treatment period, and after it ends. Because OT is associated with peri-reproductive behaviors, OT release in OAs is expected to be attenuated relative to younger adults. If OT release is low in OAs as we hypothesize, augmenting OT may increase their desire for social interactions, increase the frequency of participation in social activities and augment the number of and quality of social ties, thereby providing protection against disease, early death, cognitive decline, and depression. Research in rodents suggests that social interactions themselves may change chronic OT levels (Carter & Keverne, 2002; Carter & Altemus, 1997), in a positive feedback loop. In order to demonstrate OT as the causal mechanism, we propose to infuse oxytocin and then track the desire for, quantity of, and quality of social activities.

Interventions

DRUGoxytocin (Pitocin)

40 IU OT intranasally (IN) once-daily for 10 consecutive days

Sponsors

Claremont Graduate University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
50 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* residentially housed * English fluency

Exclusion criteria

* non ambulatory * severe psychiatric problems presently or in the recent past * severe medical problems (e.g., cancer, diabetes, advanced heart disease) * irregular heart beat * treatment using psychoactive medications (other than antiepileptics, mood stabilizers, or Ambien) * inability to adequately communicate with the research team * treatment with an experimental drug * excessive fatigue suggesting hypothyroidism

Design outcomes

Primary

MeasureTime frame
confirm increased social activities in treatment condition compared to control condition via self-report.30 days

Secondary

MeasureTime frame
Evidence of greater psychological health for treatment condition as compared to control condition.30 days

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026